drugset / Trial / NCT06361758
Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Phase 2
Withdrawn
Shanghai Zhongshan Hospital
Eastern Hepatobiliary Surgery Hospital · collabSun Yat-sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy.
Timeline
- Start
- 2024-05-31
- Primary completion
- 2026-05-31
- Completion
- 2027-05-31
Outcome
Outcome not reported
Stopped: “The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted by Akesobio.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |